Cargando…

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H, Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Österlund, Pia, Sigurdsson, Fridbjörn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, Tveit, Kjell Magne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482736/ https://www.ncbi.nlm.nih.gov/pubmed/28399112 http://dx.doi.org/10.1038/bjc.2017.93

Ejemplares similares

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
por: Thomsen, Maria, et al.
Publicado: (2016)

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
por: Hamfjord, Julian, et al.
Publicado: (2022)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
por: Smedman, Tor Magnus, et al.
Publicado: (2022)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2022)

Mechanisms involved in PGE(2)-induced transactivation of the epidermal growth factor receptor in MH(1)C(1) hepatocarcinoma cells
por: Tveteraas, Ingun Heiene, et al.
Publicado: (2012)

Generation and Characterisation of Novel Pancreatic Adenocarcinoma Xenograft Models and Corresponding Primary Cell Lines
por: Wennerström, Anna B., et al.
Publicado: (2014)

Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
Publicado: (2014)

Volumetric parameters from [ (18)F]FDG PET/CT predicts survival in patients with high‐grade gastroenteropancreatic neuroendocrine neoplasms
por: Langen Stokmo, Henning, et al.
Publicado: (2022)

Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
por: Lorentzen, Anders, et al.
Publicado: (2007)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Collagen mRNA levels changes during colorectal cancer carcinogenesis
por: Skovbjerg, Hanne, et al.
Publicado: (2009)

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
por: Tabernero, Josep, et al.
Publicado: (2021)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study
por: Skjelbred, Camilla Furu, et al.
Publicado: (2006)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Intestinal PTGS2 mRNA Levels, PTGS2 Gene Polymorphisms, and Colorectal Carcinogenesis
por: Vogel, Lotte K., et al.
Publicado: (2014)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

Home care patients in four Nordic capitals – predictors of nursing home admission during one-year followup
por: Sørbye, Liv W, et al.
Publicado: (2010)

A Nordic initiative for a more personal and accurate diagnostic pathway for prostate cancer
por: Kjosavik, Svein R., et al.
Publicado: (2020)

Evidence for the involvement of G(i2) in activation of extracellular signal-regulated kinases in hepatocytes
por: Melien, Øyvind, et al.
Publicado: (2001)

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
por: Sveen, Anita, et al.
Publicado: (2016)

Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas
por: Dasari, Arvind, et al.
Publicado: (2022)

Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
por: Angelsen, Jon-Helge, et al.
Publicado: (2015)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Nordic survey on assessment and treatment of fluid overload in intensive care
por: Zeuthen, Emilie, et al.
Publicado: (2022)

Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
por: Heslet, Lars, et al.
Publicado: (2006)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

Summary of third Nordic symposium on digital pathology
por: Lundström, Claes, et al.
Publicado: (2016)

Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma
por: Leivo, Tiina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5cskl4ke6jsi65g9u906lvnt82